| Company type | Private |
|---|---|
| Industry | |
| Founded | 2019 |
| Founder |
|
| Headquarters | , Australia |
Area served | |
| Products |
|
| Brands |
|
| Website | https://www.eucalyptus.health/ |
Eucalyptus Health is an Australian digital health company founded in 2019 that operates telehealth services including Pilot (men's health), Juniper (weight management), Software (dermatology), and Kin (reproductive health). [1] [2] The company is headquartered in Sydney and has expanded to the United Kingdom, Germany, and Japan. [3]
Eucalyptus was founded in 2019 by Tim Doyle, Charlie Gearside, Benny Kleist, and Alexey Mitko. [1] The company launched Pilot, a men's health telehealth service, as its first brand. [4] Subsequent brands included Juniper (weight management), Software (dermatology), and Kin (fertility and reproductive health). [2]
In June 2023, Eucalyptus acquired the digital assets of Jenny Craig Australia after the brand entered voluntary administration. [5]
The company raised AUD $8 million in Series A funding in May 2020, $30 million in Series B in July 2021, and $60 million in Series C in January 2022. [6] [7] A 2023 funding round raised an additional AUD $50 million. [8] The company was valued at $560 million in April 2023. [9]
Eucalyptus provides telehealth consultations, e-prescriptions, and medication delivery through partner pharmacies. [2] Services are delivered through specialized brands targeting specific health concerns:
The company reported revenue of AUD $120.9 million in FY 2024, with 60% generated from international markets. [2]
The Royal Australian College of General Practitioners (RACGP) raised concerns in 2023 about telehealth services using remote questionnaires to prescribe GLP-1 receptor agonists, questioning whether such methods provided adequate clinical assessment. [14] The Therapeutic Goods Administration (TGA) warned telehealth companies against advertising prescription-only medicines directly to consumers. [15]
During GLP-1 medication shortages in 2023–2024, Eucalyptus partnered with compounding pharmacies to provide compounded semaglutide. This practice drew criticism from pharmaceutical manufacturers and regulators. [16] [17] The Australian federal government subsequently banned pharmacy compounding of GLP-1 drugs from October 2024. [15]
Media reports in The Sydney Morning Herald and The Australian questioned whether social media and influencer campaigns for Eucalyptus brands overstated treatment results. [12] [15] ABC's Media Watch raised concerns about whether television segments promoting the company's services blurred editorial and advertising boundaries.
In response to regulatory concerns, Eucalyptus introduced phone-based GP consultations to replace asynchronous online forms. [2]
In June 2025, the TGA issued class-wide safety warnings for all GLP-1 and dual GIP/GLP-1 receptor agonists, including medications prescribed through Juniper, regarding aspiration risks during general anaesthesia. The warnings required updates to product information across all suppliers of these medications. [18]
In September 2025, Eucalyptus introduced an AI chatbot prompting warning from professional bodies about the use of artificial intelligence in weight-loss programs. [19]
In late December 2025, peak eating disorder advocacy groups expressed concerns about the rapid rollout of GLP-1 weight-loss treatments alongside their aggressive marketing on social media. There were concerns from The Australia and New Zealand Academy for Eating Disorders that these marketing techniques could target people who do not need the medication. Juniper's Black Friday sale was one of the marketing practices in question. [11]
In 2022, Eucalyptus had to cut 20% of its staff from across their brands after an investment firm pulled out of its decision to loan the company money. The investment firm was not named however the layoffs affected 50 to 60 people across multiple brands of the company. Comparable overseas start-ups, such as Ro (company) and Hims & Hers Health have faced similar struggles. [20]
In 2026, four current and former medical assistants from the Philippines spoke anonymously against Eucalyptus and their "impossible" benchmarks that were raised in 2025. It is alleged that Eucalyptus raised the number of queries that each assistant should process to more than 65 a day, with some employees assigned up to 80 new tickets. Failing to meet these metrics leads to escalation from management with fear of termination. The pressure aligns with Eucalyptus' growth however has led to increased employee turnover and dependence on AI. [21] [22]
{{cite web}}: |last= has generic name (help){{cite web}}: |first= has generic name (help)